Publicaciones en colaboración con investigadores/as de Mario Negri Institute for Pharmacological Research (16)

2019

  1. Erratum to: Estimated GFR: time for a critical appraisal (Nature Reviews Nephrology, (2018), 10.1038/s41581-018-0080-9)

    Nature Reviews Nephrology

  2. Estimated GFR: time for a critical appraisal

    Nature Reviews Nephrology, Vol. 15, Núm. 3, pp. 177-190

  3. Reply to ‘Strengths and limitations of estimated and measured GFR’

    Nature Reviews Nephrology

  4. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA

    Nephrology Dialysis Transplantation, Vol. 34, Núm. 2, pp. 208-230

2016

  1. Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: A review. Part 1: How to measure glomerular filtration rate with iohexol?

    Clinical Kidney Journal, Vol. 9, Núm. 5, pp. 682-699

  2. Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: A review. Part 2: Why to measure glomerular filtration rate with iohexol?

    Clinical Kidney Journal, Vol. 9, Núm. 5, pp. 700-704

  3. Simplified method to measure glomerular filtration rate by Iohexol plasma clearance in conscious rats

    Nephron, Vol. 133, Núm. 1, pp. 62-70

2015

  1. Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes

    The Lancet Diabetes and Endocrinology

2014

  1. Fatty kidney: Emerging role of ectopic lipid in obesity-related renal disease

    The Lancet Diabetes and Endocrinology, Vol. 2, Núm. 5, pp. 417-426

  2. Measurement of glomerular filtration rate: Internal and external validations of the iohexol plasma clearance technique by HPLC

    Clinica Chimica Acta

2013

  1. The GFR and GFR decline cannot be accurately estimated in type 2 diabetics

    Kidney International, Vol. 84, Núm. 1, pp. 164-173

2012

  1. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010

    The Lancet, Vol. 380, Núm. 9859, pp. 2197-2223

  2. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010

    The Lancet, Vol. 380, Núm. 9859, pp. 2095-2128

  3. Glomerular hyperfiltration and renal disease progression in type 2 diabetes

    Diabetes Care, Vol. 35, Núm. 10, pp. 2061-2068

  4. Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes

    Journal of the American Society of Nephrology, Vol. 23, Núm. 10, pp. 1717-1724

  5. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010

    The Lancet, Vol. 380, Núm. 9859, pp. 2163-2196